Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials

Y. Ni, G. Shi (Shanghai, China)

Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Session: Pharmacological and non-pharmacological management of COPD
Session type: Poster Discussion
Number: 2906
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Ni, G. Shi (Shanghai, China). Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials. Eur Respir J 2012; 40: Suppl. 56, 2906

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020
Year: 2021



A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016
Year: 2017



Run-in bias in randomised trials: the case of COPD medications
Source: Eur Respir J, 49 (6) 1700361; 10.1183/13993003.00361-2017
Year: 2017



Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 525s
Year: 2007

Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 32s
Year: 2006